Gazyvaro

Selected form

Obinutuzumab

Treatment option: Lymphoma, Follicular Lymphoma, Chemotherapy

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gazyvaro

Property	Description
Active ingredient	Obinutuzumab (INN)
Form	Liquid concentrate for solution for infusion
Pharmacological class	Antineoplastic/Immunomodulating Agent
General purpose	Selective depletion of B-lymphocytes
Origin	Humanized monoclonal antibody (IgG1 subclass), Biological product

What Type of Medicine is Gazyvaro?

Gazyvaro is the brand name for the active ingredient Obinutuzumab, a second-generation prescription-only biological product. It is classified as a CD20-directed cytolytic antibody, placing it within the pharmacological class of Antineoplastic Agents and Immunomodulating Agents. Obinutuzumab is a highly specialized protein, identified as a humanized monoclonal antibody of the IgG1 subclass, distinguishing it from traditional small-molecule drugs. Its distinct status as a Type II anti-CD20 monoclonal antibody is clinically recognized for its unique mechanism of cellular engagement compared to older anti-CD20 therapies.

Composition, Origin, and Unique Design

The medicine is composed solely of the active substance, Obinutuzumab, a complex protein derived through Recombinant DNA technology. The differentiating factor in Obinutuzumab's design is its glycoengineered structure, where the antibody's Fc portion is modified to reduce fucose content. This purposeful structural enhancement is characterized by the antibody's increased binding affinity for immune effector cells. This engineering results in greater cellular cytotoxicity than prior generation agents, offering a potent means of targeting specific B-cells. Gazyvaro is supplied in the physical dosage form of a sterile liquid concentrate for intravenous administration.

General Purpose and Targeted Mechanism

The primary purpose of Obinutuzumab is to achieve the selective depletion of B-lymphocytes within the body, which are cells that express the CD20 antigen on their surface. Upon binding, the antibody works by directly activating cell death pathways and effectively recruiting the patient's own immune system to destroy the targeted cells through cytolysis. This targeted action forms the basis of the drug's therapeutic use against conditions marked by B-cell overgrowth. This focused mechanism is essential for managing conditions where the reduction of this specific cell population is required.

Regulatory References

What side effects are possible with Gazyvaro?

Possible side effects and safety information

The safety profile for Obinutuzumab (Gazyvaro) is formally documented in government regulatory labeling, which outlines the expected adverse reactions, serious risks, and necessary safety precautions based on clinical trial data.

Adverse Reaction Scope

Category	Description
Key adverse reaction categories	Infusion-related reactions (IRRs) and haematological disorders, such as neutropenia and thrombocytopenia, are the most frequently observed effects in clinical trials.
Frequency classification	Adverse reactions classified as Very Common (ge 1/10) include IRRs, neutropenia, pyrexia, nausea, and upper respiratory tract infections. Tumour Lysis Syndrome (TLS), atrial fibrillation, and hypotension are classified as Common (ge 1/100 to < 1/10).
System-organ classes involved	Officially documented effects primarily involve the Blood and Lymphatic System Disorders, Infections and Infestations, and General Disorders (e.g., fever, fatigue).
Serious adverse reactions	Critical risks cited in regulatory documents include Hepatitis B Virus (HBV) reactivation (potentially fatal), Progressive Multifocal Leukoencephalopathy (PML) (a rare, serious brain infection), Tumour Lysis Syndrome (TLS), and severe/fatal infections.
Population-specific safety considerations	Older Adults (ge 65 years) have a documented higher incidence of serious adverse events. Safety data for patients with severe renal impairment (creatinine clearance < 30 mL/min) are limited.
Dose- or exposure-related patterns	IRRs and TLS are noted to occur most frequently and can be severe during the first infusion of the initial cycle. Late-onset or prolonged neutropenia may occur following treatment completion.
Safety-related restrictions or limitations	Contraindicated in patients with known hypersensitivity reactions to Obinutuzumab. HBV screening is mandated before initiation of treatment, and the medicine should not be administered in the presence of an active infection.

Resulting Safety Structure

Regulatory safety summary:

The official label clearly distinguishes between Very Common and less frequent adverse reactions, with an emphasis on Infusion-Related Reactions and Haematological Toxicities.
The safety documentation requires specific attention to serious, high-risk events like PML and HBV reactivation, establishing the need for mandatory pre-treatment screening and ongoing observation.
The safety profile is structured to account for both the timing of risk (highest during the first infusion) and the potential for increased risk in older adults.

Connection to the overall safety profile:

The official safety information for Obinutuzumab structures the understanding of risks by clearly separating frequent, generally expected effects from rare but potentially fatal systemic risks. This framework ensures that all stated risks and limitations are based strictly on data verified and approved by government authorities.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Gazyvaro overdose is structured around the risk of acute adverse events following the administration of a dose higher than recommended.

Overdose Scope

Property	Official Regulatory Statement
Documented overdose presentations	Manifestations following over-administration correspond to an increased severity of known Infusion-Related Reactions (IRRs), which may include symptoms such as hypotension, tachycardia, and dyspnea.
Physiological systems affected (as stated in label)	Potential severe effects on the Cardiovascular and Respiratory systems are documented, including the risk of acute life-threatening complications.
Population-specific overdose notes (if applicable)	Patients with pre-existing cardiac or pulmonary conditions are documented to require closer monitoring during infusion.
When immediate medical help is required (label-derived phrasing only)	Seek immediate medical attention for any sign of a severe overdose or life-threatening event.

Overdose Classifications (High-Level)

Property	Official Regulatory Statement
Severity classification (as defined in official documents)	A Grade 4 (life-threatening) reaction mandates the permanent discontinuation of the drug.
Overdose-context constraints (as defined in official documents)	No specific antidote is known for over-administration of this drug.

Resulting Overdose Structure

Official overdose statements:

Overdose manifestations are primarily described as exaggerated Infusion-Related Reactions (IRRs).
Management is restricted to the institution of symptomatic and supportive treatment.
No specific antidote is known for Gazyvaro overdose.
Immediate medical attention is required for severe or life-threatening reactions.

Connection to the overall overdose profile: Regulatory documents define the overdose profile through the acute risk of life-threatening Infusion-Related Reactions resulting from over-administration. Since no specific antidote is known, the official guidance strictly mandates that emergency help must be sought for severe manifestations, and the infusion must be permanently stopped in the event of a Grade 4 reaction.

Therapeutic Uses of Gazyvaro

What Gazyvaro Treats: Main Uses and Benefits

The primary therapeutic benefit of Gazyvaro contributes to the management of conditions marked by B-cell activity, and may assist with symptoms related to systemic imbalance and disease stabilization in particular contexts.

Gazyvaro is used in the treatment of several conditions, demonstrating its broad role in managing B-cell driven pathologies.

This targeted therapy is commonly used to help with the management of B-cell malignancies, including Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL), as well as the autoimmune condition Active Lupus Nephritis. Gazyvaro is relevant in clinical settings that involve acute or unstable symptom patterns, such as those related to high systemic cancer burden or active organ inflammation. The approach may support the goal of achieving a substantial disease response and may support a longer time without disease progression in patients with previously untreated, relapsed, or refractory CLL and FL.

Immunomodulatory and Supportive Role

Gazyvaro is applied in addressing symptom clusters linked to organ-specific functional stress, such as those seen in Active Lupus Nephritis. This action supports efforts toward a substantial response in kidney function, assisting with maintaining functional stability where symptoms interfere with routine activities.

Quick Fact: Management of B-Cell Pathologies
Gazyvaro is applied in addressing symptom clusters linked to organ-specific functional stress and systemic imbalance associated with B-cell activity.

Regulatory References

European Medicines Agency Gazyvaro EPAR Product Information

Eligibility and Restrictions for Use

Eligibility Scope

Gazyvaro is strictly contraindicated in patients with a known history of hypersensitivity reactions, such as anaphylaxis or serum sickness, to obinutuzumab or any of the product’s components. Use is prohibited in patients with an active infection and those with active Hepatitis B Virus (HBV) liver disease.

Age and Organ Function

Population	Regulatory Status
Pediatric Use (<18 years)	Safety and efficacy have not been established
Geriatric Use (Older Adults)	No dose adjustment is required
Severe Renal Impairment (CrCl < 30 mL/min)	Safety and efficacy have not been established

Condition-Based Restrictions

Eligibility requires prior screening for HBV infection. Patients with a history of recurring or chronic infections, as well as those with pre-existing cardiac or pulmonary conditions, must be monitored closely. For women of reproductive potential, Gazyvaro can cause fetal harm, and the use of effective contraception is required during and for a specific period after treatment. Women should not breastfeed during treatment and for at least six months following the last dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Gazyvaro (Obinutuzumab) is based on pharmacodynamic effects, as regulatory information states the drug is not an inhibitor, inducer, or substrate of CYP450 enzymes or drug transporters.

Documented Pharmacodynamic Interactions

Interacting Product Category	Official Interaction Statement
Live Virus Vaccines	Immunization is not recommended during treatment and until B-cell recovery, due to decreased vaccine effectiveness and increased risk of infection.
Antihypertensive Treatments	Obinutuzumab may enhance the risk of hypotension (low blood pressure) during infusion, a risk managed by a required timing separation.
Chlorambucil (Co-administered Chemotherapy)	Co-administration is reported to increase the risk of thrombocytopenia (low platelet count) and subsequent hemorrhage events.

Official Regulatory Constraints

To manage the hemodynamic risk, prescribers should consider withholding antihypertensive treatments for 12 hours prior to, throughout, and for the first hour after each Gazyvaro infusion. Regarding population constraints, the safety and efficacy of Gazyvaro have not been established in patients with severe renal impairment (CrCl < 30 mL/min) or impaired hepatic function.

Mechanism of Action

How Gazyvaro Works

The mechanism of action for Gazyvaro (Obinutuzumab) is restricted to highly targeted pharmacodynamic processes, involving the selective elimination of immune cells that express the CD20 antigen.

Selective Molecular Targeting and Immune Recruitment

The drug is a glycoengineered Type II monoclonal antibody precisely targeted to the CD20 antigen on the surface of B-lymphocytes. This binding activates two major cellular destruction pathways. First, the glycoengineering of the Fc region enhances the drug's affinity for Fc gamma receptors on immune executioners, notably Natural Killer (NK) cells, resulting in robust Antibody-Dependent Cell-mediated Cytotoxicity (ADCC). Second, its unique Type II binding pattern induces intense clustering and aggregation of CD20, directly triggering the B-cell's internal death signaling.

Dual Cytolytic Cascade Activation

Gazyvaro exerts its effect through a dual cytolytic cascade. The ADCC pathway uses recruited immune cells to physically destroy the targeted B-lymphocytes. Simultaneously, the strong CD20 clustering directly initiates Programmed Cell Death (apoptosis). This combined mechanism results in the rapid and profound systemic depletion of CD20-positive B-lymphocytes. This physiological consequence alters the immune cell population profile. The mechanism is fundamentally limited by the existence of CD20-negative cells which cannot be targeted.

Dosage and Administration Information

Official Administration Guidelines for Gazyvaro

Gazyvaro (obinutuzumab) is administered exclusively through intravenous (IV) infusion and must not be given as a rapid injection or bolus. The medicine is supplied as a concentrate that requires dilution with 0.9% sodium chloride solution before it can be used, and it must never be prepared with dextrose solutions. Administration must take place under the close supervision of an experienced physician in a setting where full resuscitation facilities are immediately available.

Standard Dosing and Schedule

Treatment follows a defined cyclic regimen, with the standard dose set at 1,000 mg per infusion across all approved uses. The frequency and timing are highly structured based on the treatment phase:

Chronic Lymphocytic Leukemia (CLL): The regimen consists of six 28-day cycles. Notably, the initial 1,000 mg dose in Cycle 1 is typically split over Day 1 (100 mg) and Day 2 (900 mg) to manage the first infusion. Subsequent cycles require a single 1,000 mg dose on Day 1.
Follicular Lymphoma (FL): The dose is 1,000 mg per infusion. Following the initial induction cycles, maintenance therapy is administered as 1,000 mg once every two months for a duration of up to two years or until disease progression.

Procedural Instructions and Adjustments

The infusion rate is precisely controlled, starting slow and escalating based on patient tolerability during the administration process. If a planned dose is missed, it should be administered as soon as possible, and the subsequent schedule must be adjusted to maintain the correct time interval between infusions. No specific dose adjustments are explicitly mandated for older adults in the official label.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Gazyvaro (Obinutuzumab)

The research for Gazyvaro (Obinutuzumab) is based on several large-scale clinical trials designed to observe patterns related to the study regimen for specific conditions. This overview describes the research landscape, not the treatment’s specific effects or suitability for any individual.

Evidence for Use in Chronic Lymphocytic Leukaemia (CLL)

The main studies involved adults who were often older and had co-existing health conditions, which defined the population as those generally unsuitable for intensive chemotherapy. The trials examined the Gazyvaro combination against active control or single-agent regimens. The studies focused on measuring the time without disease progression (PFS), a metric used in research exploring how the disease changes over time, and the overall response rate (ORR).

Evidence for Use in Follicular Lymphoma (FL)

Studies for Follicular Lymphoma (FL) include Phase III randomized controlled trials (RCTs) that compared Gazyvaro regimens against rituximab-based regimens. Researchers monitored outcomes primarily focused on the time without disease progression (PFS) during both initial treatment and maintenance phases for both newly diagnosed and relapsed patients. Long-term data concerning overall survival in these comparative trials continue to mature, limiting the certainty on this metric in the final trial reports.

Evidence for Use in Active Lupus Nephritis (LN)

The evidence is derived from a Phase III RCT that utilized a double-blind, placebo-controlled design. The primary research focus was on the achievement of a Complete Renal Response (CRR) at a pre-specified time point, an outcome related to systemic or functional imbalance. The trials also described patterns where the time until an unfavorable kidney outcome was monitored in the Gazyvaro group and compared to the control group. Evidence is limited regarding the long-term sustained response beyond the two-year period.

Gaps and Uncertainties in the Research Evidence

There is limited information for long-term outcomes regarding overall survival across all three indications. Evidence highlights what is known—and what is still uncertain. Data for certain groups remain insufficient, meaning results apply only to the populations studied. While Gazyvaro was evaluated in comparative studies against rituximab, comparative evidence against newer classes of treatments is often lacking as research is ongoing.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Gazyvaro (FAQ)

Q: Is Gazyvaro considered a type of chemotherapy?

A: Gazyvaro is classified as a specialized drug known as an Antineoplastic Agent and a CD20-directed cytolytic antibody. According to official product information, it is a monoclonal antibody protein, which distinguishes it from traditional, small-molecule chemotherapy drugs. Its mechanism involves specifically targeting certain immune cells rather than generally targeting rapidly dividing cells.

Q: How is Gazyvaro different from other treatments for CLL or NHL?

A: Gazyvaro is a glycoengineered Type II anti-CD20 monoclonal antibody. Regulatory information indicates that its unique structure is associated with enhanced cellular cytotoxicity compared to prior-generation anti-CD20 agents. This means it has a differentiated mechanism for targeting and depleting B-cells.

Q: How long does the Gazyvaro infusion usually take?

A: The length of the infusion varies depending on the treatment cycle and how well the treatment is tolerated. The initial dose is typically administered over several hours and may be split over two days. For subsequent cycles, if the prior infusion was well-tolerated, a shorter infusion time of approximately 90 minutes may be used, as described in the administration guidelines.

Q: What should a patient expect during the first Gazyvaro treatment?

A: The first dose is split over two days, a schedule defined in the official guidelines to help manage the risk of severe reactions that are noted to occur most frequently during this initial cycle. Regulatory documents highlight that Infusion-Related Reactions (IRRs) and Tumour Lysis Syndrome (TLS) are key risks during this period, requiring close monitoring.

Q: Are there any long-term side effects associated with Gazyvaro?

A: The official regulatory documentation notes that a low white blood cell count, known as neutropenia, can be of late onset—occurring more than 28 days after treatment completion—or prolonged—lasting longer than 28 days. This indicates that effects on the blood system may persist after the treatment course is finished, and patients are monitored for this.

Q: How does Gazyvaro affect liver or kidney function?

A: Official information states that the safety and efficacy of Gazyvaro have not been established in patients with severe renal impairment (very low kidney function) or impaired hepatic function (liver function). Separately, the drug carries a serious risk of Hepatitis B Virus (HBV) reactivation, which can cause liver failure and requires mandatory pre-treatment screening.

Q: How can infusion reactions to Gazyvaro be managed or lessened?

A: Management procedures described in regulatory documents include reducing the rate or temporarily interrupting the infusion if a patient experiences symptoms of an Infusion-Related Reaction (IRR). Depending on the severity of the reaction, the infusion may be restarted at a slower rate or permanently stopped.

Q: Does Gazyvaro interact with common over-the-counter pain relievers?

A: Regulatory documents describe a premedication regimen that includes taking an oral analgesic or anti-pyretic (such as acetaminophen/paracetamol) before the infusion to reduce the risk of reactions. Specific interactions with other non-prescription pain relievers are not explicitly detailed in the official product information.

Q: Does Gazyvaro cause hair loss?

A: Official regulatory documentation lists adverse reactions from clinical trials by frequency. Hair loss, or alopecia, is not listed among the most Very Common or Common adverse reactions (those occurring in 1 out of 100 people or more) in the product label.

Q: How quickly does Gazyvaro start working after the first dose?

A: The mechanism of action is described in official sources as resulting in the rapid and profound systemic depletion of the targeted B-lymphocytes. However, the time required for a patient to experience a clinical response or feel the drug's therapeutic effects is not specifically detailed or quantified in the official product labeling.

Q: Will I feel the effect of Gazyvaro immediately?

A: Many patients may experience symptoms related to Infusion-Related Reactions (IRRs) during the administration. These common reactions can include fatigue, nausea, fever, or chills, and they often occur during or within 24 hours of the first dose. These are reactions to the infusion, not necessarily the therapeutic effect.

Q: Are there ongoing clinical trials for Gazyvaro?

A: Official regulatory records and news indicate that Gazyvaro has been or is being investigated in additional studies beyond its primary uses. This includes research for diseases such as lupus nephritis and idiopathic nephrotic syndrome, suggesting continued investigation in new populations.

Q: Where can I find official information about Gazyvaro research?

A: Information regarding research studies for Gazyvaro, including those that are ongoing or completed, is publicly available. These details can be accessed through government-sponsored resources, such as the NIH Clinical Trials database or your national health authority's clinical trial registry.

Q: Does Gazyvaro have a Black Box Warning?

A: Yes, the Prescribing Information provided by the U.S. FDA includes a Boxed Warning. This warning highlights serious risks cited in the document, which include Hepatitis B Virus (HBV) Reactivation and Progressive Multifocal Leukoencephalopathy (PML), requiring special attention.

Q: Does Gazyvaro have an effect on fertility?

A: The specific effect of Gazyvaro on human fertility is unknown, according to official product information. However, regulatory guidance indicates that the drug can cause fetal harm during pregnancy, requiring women of reproductive potential to use effective contraception during and for a specified time period after treatment.

Q: Can Gazyvaro treatment be stopped suddenly?

A: Permanent discontinuation of treatment is described in the official label as a necessary step if a patient experiences specific severe reactions. These include a life-threatening Infusion-Related Reaction (IRR) or a confirmed hypersensitivity reaction to the drug.

Q: Is Gazyvaro a permanent cure for cancer?

A: Clinical studies supporting the drug's use focus on measures of disease control and progression, such as Progression-Free Survival (PFS) and the Overall Response Rate (ORR). Official regulatory documentation describing the drug's efficacy does not state that Gazyvaro is a permanent cure for cancer.

How should Gazyvaro be stored and disposed of?

How to Store and Dispose of Gazyvaro?

Regulatory information dictates specific storage and handling requirements for Gazyvaro (Obinutuzumab) concentrate and the diluted solution to maintain product integrity.

Storage Requirement	Official Regulatory Statement
Unopened Vial Storage	Store in a refrigerator (2 C to 8 C / 36 F to 46 F) and protect from light by keeping the container in the outer carton.
Prohibitions	Do not freeze the concentrate or the diluted solution. Do not shake the vial or the prepared infusion.
Diluted Solution Stability	The prepared solution may be stored at 2 C to 8 C for up to 24 hours. If refrigerated, it must be used immediately after reaching room temperature.
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal	As a single-dose vial, any unused portion must be discarded. Dispose of all waste material and expired product according to local regulatory requirements for pharmaceutical waste.